Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements

ConditionGLP - 1
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorPenn State University

About this trial

The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. The primary question we aim to answer is: do GLP-1 medications reduce an individual's vulnerability to external triggers that drive food cravings and consumption?

Participants will:

* report daily food consumption for a total of 10 days, * receive eight daily prompts to view food or non-food related advertisements, and respond to a short 9-question survey for 7 days, * answer several questionnaires, * and complete two in-person visits to complete a virtual reality food selection task.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults (18+) with overweight or obesity (BMI >25 kg/m2)

On an injectable form of tirzepatide GLP-1 medication at a minimum dose of 7.5 mg, taking it as prescribed by their doctor

Not currently taking an incretin-based medication at baseline other than the GLP-1 medication

Fluent in English

Disqualifiers

Do not have consistent access to a smart phone that can access the study software

Diagnosed with cognitive or physical disability or epilepsy

Adults taking a compound GLP-1

Trial design

Design model

Parallel

Treatments tested in this trial

  • Food advertisements

    Behavioral

    Videos and images of food and beverage advertisements from popular brands and/or restaurants

  • Tech advertisements

    Behavioral

    Video and photo advertisements of popular tech tools

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Food advertisement groupExperimental treatment 1 intervention
Group B: Tech advertisement groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Mean food cue reactivity scores in the afternoon

Average scores of craving levels for each group following afternoon advertisement viewing sessions

Time frame
7-day period of all afternoon survey responses
2

Mean food cue reactivity scores in the morning

Average scores of craving levels for each group following morning advertisement viewing sessions

Time frame
7-day period of all morning survey responses
3

Mean food cue reactivity scores in the evening

Average scores of craving levels for each group following evening advertisement viewing sessions

Time frame
7-day period of all evening survey responses
4

Mean food cue reactivity scores overall

Average scores of craving levels for each group over all viewing sessions

Time frame
7-day period of all survey responses

Secondary outcomes

1

Change from baseline in energy density of foods selected in the virtual buffet

Time frame
Baseline and 7 days
2

Changes in food noise since being on medication questionnaire

Questionnaire assessing various aspects of food noise at present compared to before the medication

Time frame
Baseline
3

Changes in reasons for purchasing foods questionnaire

A questionnaire that assesses how five factors impact purchasing choices, and how the main factors have changed between prior to starting the medication and after.

Time frame
Baseline
4

Individual Food Cue Responsiveness--Trait

Time frame
Baseline

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Penn State University

Lead sponsor

Penn State Health

Collaborator

This trial is not recruiting at the moment. You can still explore other options: